Global Deferiprone Market By Market Size
Deferiprone Market was valued at US$39.5 million in 2024 and is projected to grow at a compound annual growth rate of 14% to reach US$130.2 million by 2034.
Deferiprone is used to remove excess iron from the body in people with sickle cell anemia and thalassemia, a genetic illness that causes a decrease in red blood cell count, as well as in adults and children three years of age and older.
Deferiprone's market is expected to expand as the fatal thalassemia disorder becomes more common. About 4.4 out of every 10,000 live births are affected by thalassemia. In the broader populace, scanning characteristics Although 5% of people globally have a globin variant, just 1.7% of people on Earth have the alpha or beta thalassemia characteristic. By better knowing these facts, the healthcare industry can increase demand for the Deferiprone Market.